{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:04:58Z","timestamp":1790024698639,"version":"4.0.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clcc.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:37Z","timestamp":1787181937000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Immune Checkpoint Inhibitor-Based Neoadjuvant Therapy Combinations in Proficient Mismatch Repair\/Microsatellite Stable Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","author":[{"given":"Xiya","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanxi","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingna","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clcc.2026.08.002_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.clcc.2026.08.002_bib0002","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41575-024-00900-9","article-title":"Future direction of total neoadjuvant therapy for locally advanced rectal cancer","volume":"21","author":"Kagawa","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clcc.2026.08.002_bib0003","doi-asserted-by":"crossref","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2026.08.002_bib0004","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.6004\/jnccn.2022.0051","article-title":"Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Benson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.clcc.2026.08.002_bib0005","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/DCR.0000000000003057","article-title":"The American society of colon and rectal surgeons clinical practice guidelines for the management of rectal cancer 2023 supplement","volume":"67","author":"Langenfeld","year":"2024","journal-title":"Dis Colon Rectum"},{"issue":"13","key":"10.1016\/j.clcc.2026.08.002_bib0006","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1245\/s10434-011-1822-0","article-title":"Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for ct3 rectal cancer: implications for local excision surgical strategies","volume":"18","author":"Belluco","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.clcc.2026.08.002_bib0007","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clcc.2026.08.002_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.30097","article-title":"Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis","volume":"3","author":"Kasi","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"28","key":"10.1016\/j.clcc.2026.08.002_bib0009","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO.24.01160","article-title":"Management of locally advanced rectal cancer: ASCO guideline","volume":"42","author":"Scott","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.08.002_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.08.002_bib0011","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.clcc.2026.08.002_bib0012","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clcc.2026.08.002_bib0013","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","article-title":"A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat Immunol"},{"issue":"25","key":"10.1016\/j.clcc.2026.08.002_bib0014","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clcc.2026.08.002_bib0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.clcc.2026.08.002_bib0016","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41392-022-01264-9","article-title":"Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.clcc.2026.08.002_bib0017","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.clcc.2026.08.002_bib0018","doi-asserted-by":"crossref","first-page":"7376","DOI":"10.1038\/s41598-020-64408-3","article-title":"Transcriptional upregulation of NLRC5 by radiation drives STING- and interferon-independent MHC-I expression on cancer cells and T cell cytotoxicity","volume":"10","author":"Zebertavage","year":"2020","journal-title":"Sci Rep."},{"issue":"9","key":"10.1016\/j.clcc.2026.08.002_bib0019","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/codi.17090","article-title":"Preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor administration for locally advanced rectal cancer: a study protocol of a randomized phase II\/III trial (STELLAR II study)","volume":"26","author":"Zhang","year":"2024","journal-title":"Colorectal Dis"},{"issue":"1","key":"10.1016\/j.clcc.2026.08.002_bib0020","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JS9.0000000000001960","article-title":"Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study","volume":"111","author":"Wang","year":"2025","journal-title":"Int J Surg"},{"key":"10.1016\/j.clcc.2026.08.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.clcc.2026.08.002_bib0022","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.clcc.2026.08.002_bib0023","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"Int J Evid Based Healthc"},{"key":"10.1016\/j.clcc.2026.08.002_bib0024","doi-asserted-by":"crossref","first-page":"S273","DOI":"10.1016\/j.annonc.2024.08.154","article-title":"146P Biomarkers and intrinsic\/acquired resistance mechanisms for atezolizumab plus chemoradiotherapy in MSS locally advanced rectal cancer: an exploratory analysis of a single center, phase II study","volume":"35","author":"Tang","year":"2024","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clcc.2026.08.002_bib0025","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1200\/JCO.2021.39.15_suppl.3511","article-title":"Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): the AVANA study","volume":"39","author":"Salvatore","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clcc.2026.08.002_bib0026","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1200\/JCO.2023.41.16_suppl.3616","article-title":"The ave-rec trial: phase II trial of PD-L1\/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4\/N1-2 rectal cancer\u2014toxicity and interim efficacy data","volume":"41","author":"Michael","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2026.08.002_bib0027","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.annonc.2024.05.257","article-title":"250P Short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma: final analysis of the phase II Averectal trial","volume":"35","author":"Chehade","year":"2024","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clcc.2026.08.002_bib0028","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.annonc.2024.05.255","article-title":"248P Preliminary results from CA209-8M4: a phase II trial evaluating the addition of nivolumab (nivo) to total neoadjuvant treatment (TNT) for locally advanced rectal cancer (LARC)","volume":"35","author":"Brenner","year":"2024","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clcc.2026.08.002_bib0029","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e15647","article-title":"Efficacy and safety of camrelizumab and apatinib combined with neoadjuvant concurrent chemoradiation for MSS locally advanced rectal cancer","volume":"41","author":"Jiang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.clcc.2026.08.002_bib0030","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/j.annonc.2023.09.1786","article-title":"595P The DUREC trial: durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)","volume":"34","author":"Capdevila Castillon","year":"2023","journal-title":"Ann Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clcc.2026.08.002_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e15602","article-title":"Preliminary efficacy and safety of total neoadjuvant therapy combined with PD-L1 blockade in pMMR\/MSS locally advanced rectal cancer (ESTIMATE): a prospective, single-arm, phase II trial","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.clcc.2026.08.002_bib0032","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1016\/j.annonc.2024.08.639","article-title":"570P a phase II clinical study of fruquintinib (Fru) combined with toripalimab (Tor) and short-course radiotherapy (SCRT) as neoadjuvant therapy for locally advanced rectal cancer (LARC)","volume":"35","author":"Chen","year":"2024","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clcc.2026.08.002_bib0033","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/j.annonc.2024.05.256","article-title":"249P The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and cadonilimab for locally advanced rectal cancer: the preliminary findings of prospective, multicenter phase II trial","volume":"35","author":"Feng","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.08.002_bib0034","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","article-title":"Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"4_suppl","key":"10.1016\/j.clcc.2026.08.002_bib0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1200\/JCO.2022.40.4_suppl.099","article-title":"Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2","volume":"40","author":"George","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clcc.2026.08.002_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101824","article-title":"Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial","volume":"8","author":"Grassi","year":"2023","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.clcc.2026.08.002_bib0037","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamasurg.2023.7996","article-title":"Total neoadjuvant therapy with PD-1 blockade for high-risk proficient mismatch repair rectal cancer","volume":"159","author":"Li","year":"2024","journal-title":"JAMA Surgery"},{"issue":"Suppl 2","key":"10.1016\/j.clcc.2026.08.002_bib0038","doi-asserted-by":"crossref","first-page":"S432","DOI":"10.1016\/j.annonc.2023.09.1790","article-title":"599P R-IMMUNE: a phase Ib\/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)","volume":"34","author":"Carrasco","year":"2023","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clcc.2026.08.002_bib0039","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.annonc.2024.05.254","article-title":"247P radiotherapy (RT), atezolizumab (atezo) and bevacizumab (bev) to increase organ preservation in rectal cancer: the TARZAN study","volume":"35","author":"de Gooyer","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clcc.2026.08.002_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003554","article-title":"Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J ImmunoTher Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.clcc.2026.08.002_bib0041","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.annonc.2023.04.228","article-title":"P-172 VOLTAGE cohort D: preoperative chemoradiotherapy followed by consolidation nivolumab plus ipilimumab in patients with locally advanced rectal cancer","volume":"34","author":"Takahashi","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2026.08.002_bib0042","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","article-title":"Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2 Suppl","key":"10.1016\/j.clcc.2026.08.002_bib0043","article-title":"3097 preoperative short-course radiotherapy combined with chemotherapy and tislelizumab for locally advanced middle-low rectal cancer: a randomized phase I\/II clinical study","volume":"120","author":"Li","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.clcc.2026.08.002_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2024.07.004","article-title":"Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: a randomized clinical trial","volume":"42","author":"Xiao","year":"2024","journal-title":"Cancer Cell"},{"issue":"Suppl 1","key":"10.1016\/j.clcc.2026.08.002_bib0045","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/j.annonc.2024.05.250","article-title":"243P neoadjuvant XELOX chemotherapy with or without cadonilimab in locally advanced pMMR rectal cancer: preliminary results from a randomized, open-label phase II trial","volume":"35","author":"Zhou","year":"2024","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"10.1016\/j.clcc.2026.08.002_bib0046","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.2025.43.4_suppl.150","article-title":"Short-course radiotherapy-based total neoadjuvant therapy combined with tislelizumab in the treatment of locally advanced rectal cancer (Neo-STAR): early outcomes of a prospective, randomized phase II trial","volume":"43","author":"Wu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clcc.2026.08.002_bib0047","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial","volume":"7","author":"Rahma","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.clcc.2026.08.002_bib0048","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41591-024-03360-5","article-title":"Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial","volume":"31","author":"Yang","year":"2025","journal-title":"Nat Med"},{"issue":"2 Suppl","key":"10.1016\/j.clcc.2026.08.002_bib0049","article-title":"3021 preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor administration for locally advanced rectal cancer: the initial results of a randomized phase II\/III trial (STELLAR II study)","volume":"120","author":"Li","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"28","key":"10.1016\/j.clcc.2026.08.002_bib0050","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.23.02261","article-title":"Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer: TORCH","volume":"42","author":"Xia","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2026.08.002_bib0051","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial","volume":"35","author":"Lin","year":"2024","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clcc.2026.08.002_bib0052","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/bjs\/znad120","article-title":"Total neoadjuvant therapy versus chemoradiotherapy for locally advanced rectal cancer: Bayesian network meta-analysis","volume":"110","author":"Wu","year":"2023","journal-title":"Br J Surg"},{"key":"10.1016\/j.clcc.2026.08.002_bib0053","article-title":"Neoadjuvant immunotherapy for DNA mismatch repair proficient\/microsatellite stable non-metastatic rectal cancer: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.clcc.2026.08.002_bib0054","article-title":"The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.clcc.2026.08.002_bib0055","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/SLA.0000000000003471","article-title":"Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes","volume":"271","author":"Petrelli","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.clcc.2026.08.002_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1515756","article-title":"Total neoadjuvant therapy based on short-course radiotherapy versus standard long-course chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Pu","year":"2024","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.clcc.2026.08.002_bib0057","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3390\/biom14040448","article-title":"IFN-type-I response and systemic immunity in rectal adenocarcinoma patients treated with conventional or hypofractionated neoadjuvant radiotherapy","volume":"14","author":"Koukourakis","year":"2024","journal-title":"Biomolecules"},{"issue":"10","key":"10.1016\/j.clcc.2026.08.002_bib0058","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.3390\/curroncol31100429","article-title":"Lymphopenia induced by different neoadjuvant chemo-radiotherapy schedules in patients with rectal cancer: bone marrow as an organ at risk","volume":"31","author":"Nanos","year":"2024","journal-title":"Current Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2026.08.002_bib0059","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1158\/1078-0432.CCR-25-2733","article-title":"Differential immunologic effects of short-course and long-course radiotherapy in locally advanced rectal cancer","volume":"32","author":"Hillson","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"29","key":"10.1016\/j.clcc.2026.08.002_bib0060","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202517450","article-title":"Hypofractionated radiotherapy induces ISG15+MHC-I+ neutrophils to augment anti-tumor immunity and prime immune checkpoint blockade responses in rectal cancer","volume":"13","author":"Liu","year":"2026","journal-title":"Adv Sci"},{"issue":"31","key":"10.1016\/j.clcc.2026.08.002_bib0061","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2012.42.9597","article-title":"Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04","volume":"30","author":"Ngan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2026.08.002_bib0062","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/bjs.5506","article-title":"Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer","volume":"93","author":"Bujko","year":"2006","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.clcc.2026.08.002_bib0063","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"issue":"5","key":"10.1016\/j.clcc.2026.08.002_bib0064","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","article-title":"Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics","volume":"19","author":"Yamaguchi","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.08.002_bib0065","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","article-title":"Mechanisms regulating PD-L1 expression on tumor and immune cells","volume":"7","author":"Chen","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"15","key":"10.1016\/j.clcc.2026.08.002_bib0066","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clcc.2026.08.002_bib0067","doi-asserted-by":"crossref","first-page":"e1555","DOI":"10.1002\/onco.13824","article-title":"Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis","volume":"26","author":"Liu","year":"2021","journal-title":"Oncologist"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:28:50Z","timestamp":1790022530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002826000538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":67,"alternative-id":["S1533002826000538"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2026.08.002","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Immune Checkpoint Inhibitor-Based Neoadjuvant Therapy Combinations in Proficient Mismatch Repair\/Microsatellite Stable Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}